SLCO1B1 and malignant colon neoplasm: The experiments performed here using human colon cancer cells have demonstrated that our therapeutic construct is able to induce higher sensitivity to OATP1B1 antitumor substrates, which occurs specifically in colon cancer cells that overexpress MRP2.